HOME >> BIOLOGY >> NEWS
Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation

Charlestown, MA, July 14, 2003 -- In this issue of the journal Virology, (Vol. 312, Number 2, August 1, 2003) researchers from Immerge BioTherapeutics, Inc., (a BioTransplant Incorporated (Nasdaq:BTRN) /Novartis Pharma AG (NYSE:NYS) joint venture company) announced that recombination between porcine and human endogenous retrovirus was not detected when using sensitive laboratory tests, leading the authors to conclude that the creation of a new virus from the two was highly unlikely. Although the risk of recombination is purely theoretical, it has been of concern to xenotransplant researchers. This study represents an important finding and the most recent advance in the Immerge safety program, which is dedicated to addressing potential issues in the safety risk of pig-to-human xenotransplantation.

"We utilized a laboratory model to simulate PERV (porcine endogenous retrovirus) transmission by infecting human cells with the virus," said Dr Clive Patience, Director of the Safety Program at Immerge. "We found that human retrovirus elements were not detectable in the PERV particles released from the infected human cells. These results are encouraging, as we used very sensitive assays that can detect 1 out of 50,000 to 1 out of 10 million elements. Therefore, if human cells were ever to become infected by PERV, the likelihood of porcine and human viruses recombining to form a novel infectious virus is extremely remote."

PERV is a natural virus in pigs, but does not cause any disease in these animals. In certain laboratory conditions PERV can infect cells from other species, including some human cells. However, there are no indications that PERV infection has occurred in living individuals, including humans that have been treated with pig tissues or those that are in regular direct contact with living pig cells or tissues.

"The risk of cross-species spread of PERV should be balanced by the potential efficacy of the transplanted tissue," comme
'"/>

Contact: Susan Hayes
shayesconsult@earthlink.net
212-533-4472
S. Hayes Consulting
14-Jul-2003


Page: 1 2

Related biology news :

1. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine
2. Immerge BioTherapeutics announces identification of PERV receptor
3. Immerge biotherapeutics identifies miniature swine that do not transmit pig retrovirus to humans
4. Secretary of Energy announces seven E.O. Lawrence Award Winners
5. Popular Science announces Third Annual Brilliant 10
6. The American Phytopathological Society announces 2004 awards
7. NSF announces six FIBR awards to tackle some of biologys most challenging questions
8. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
9. JGI announces community sequencing program portfolio
10. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics
11. National Corn Growers Association announces valuable maize genome data now available to scientists

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2020)... ... June 11, 2020 , ... ... a significant expansion of its forensic genealogy team. Bode’s Forensic Genealogy Service ... proven forensic genealogy and DNA analysis methods. The team has added experienced genealogists, ...
(Date:6/5/2020)... ... ... Greffex, a pioneering vaccine and gene therapy company based in Houston, Texas, ... for a global perspective to make an impact in a post pandemic world,” said ... an independent, director of the company. , “The Greffex board is excited to have ...
(Date:5/28/2020)... Del. (PRWEB) , ... May ... ... Biosciences (DuPont) has announced a new enzyme solution for adjunct liquefaction: AMYLEX® ... alike including the ability to expand into new segments with locally-sourced raw ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., a ... of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. ... lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine ...
(Date:7/1/2020)... GREEN, Ohio (PRWEB) , ... June 29, 2020 ... ... that offers access to competitively procured purchasing contracts to its membership, recently named ... to provide TIPS members with the opportunity to purchase ergonomic seating, cafeteria tables, ...
(Date:6/28/2020)... Conn. (PRWEB) , ... June 25, 2020 , ... ... formed to advance photodynamic therapy for treating cancer, today announced the company has ... York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to Roswell ...
(Date:6/23/2020)... ... June 22, 2020 , ... Regen Suppliers, the one ... includes buy three, get the fourth unit free with no limit on the ... known as exosomes, have been a game changer for regenerative therapies. The products ...
Breaking Biology Technology:
Cached News: